Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Vaxcyte, Inc. - Common Stock
(NQ:
PCVX
)
73.82
UNCHANGED
Delayed Quote
Updated: 4:15 PM EDT, Oct 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Vaxcyte, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
Vaxcyte Catapults 34% As It Looks To Take On Pfizer In A $10 Billion Market
↗
September 03, 2024
The company is looking to take on Pfizer in the massive pneumococcal conjugate vaccine market.
Via
Investor's Business Daily
Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older
September 03, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte to Host Webcast and Conference Call to Present Topline Results from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older
September 02, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Peering Into Vaxcyte's Recent Short Interest
↗
August 27, 2024
Via
Benzinga
PCVX Stock Earnings: Vaxcyte Beats EPS for Q1 2024
↗
May 08, 2024
PCVX stock results show that Vaxcyte beat analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
Recap: Vaxcyte Q4 Earnings
↗
February 27, 2024
Via
Benzinga
Earnings Scheduled For February 27, 2024
↗
February 27, 2024
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million.
Via
Benzinga
Vaxcyte Reports Second Quarter 2024 Financial Results and Provides Business Update
August 06, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte Appoints John Furey to Board of Directors
July 02, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update
May 08, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaccine Player Vaxcyte Has Advantage Over Pfizer, Merck's Pneumococcal Shots - Analyst Says
↗
April 10, 2024
The global PCV market, valued at ~$8 billion annually, is poised for significant growth, estimated to reach ~$12 billion soon. Market dynamics are shifting towards adults, potentially doubling with the...
Via
Benzinga
Vaxcyte to Present at the 23rd Annual Needham Virtual Healthcare Conference
April 02, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Oracle To Rally Around 40%? Here Are 10 Top Analyst Forecasts For Tuesday
↗
March 12, 2024
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants
March 04, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
February 27, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
February 15, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
February 02, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference
February 01, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte Announces Pricing of $750 Million Public Offering
January 30, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
January 30, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte Completes Enrollment of Phase 1/2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease (IPD) in Adults Aged 50 and Older
January 29, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte Appoints Whitney Jones as Chief People Officer
January 16, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
"Top Pick for 2024": Analyst Bullish On Phathom Pharmaceuticals On Voquezna Launch In Erosive GERD, Projecting $55.6M In Sales
↗
January 05, 2024
Needham analyst Joseph Stringer reiterated a Buy rating on Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT),
Via
Benzinga
Vaxcyte Provides Clinical and Regulatory Progress Update on Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV) Franchise
January 04, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaccine Player Vaxcyte Can Potentially Disrupt Pfizer's 20-Plus-Year Near Monopoly, Says Analyst
↗
December 07, 2023
Mizuho Securities initiated coverage on Vaxcyte Inc (NASDAQ: PCVX), a vaccine company targeting bacterial infectious diseases (primarily for disease prevention).
Via
Benzinga
VAX-24 Phase 1/2 Adult Proof-of-Concept Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 24-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate
December 04, 2023
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte Appoints Jacks Lee to Board of Directors
November 28, 2023
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control Over Manufacturing and Development of Cell-Free Extract for its Vaccine Candidates
November 27, 2023
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Adults
November 09, 2023
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte Reports Third Quarter 2023 Financial Results and Provides Business Update
November 06, 2023
From
Vaxcyte, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1
